Cardiovascular morbidities in postoperative colorectal cancer patients

Abstract

This retrospective observational study investigated the long-term prevalence of new-onset cardiovascular disease (CVD) and the predictive role of atherosclerotic plaque in the aorta and iliac arteries for CVD in postoperative colorectal cancer (CRC) patients who received surgical treatment between 2014 and 2015. CVD included coronary or cerebrovascular diseases which required treatment and new-onset CVD included peri-and postoperatively diagnosed CVDs or aggravated CVDs that required additional treatment during follow-up. Of the 2,875 patients included in this study, the prevalence of CVD was 8.9% (255/2875) and 141 (4.9%) developed new-onset CVD. Maximum arterial stenosis in the aorta or iliac arteries occurred in 40.8 ± 18.6% of patients with new-onset CVD and 11.6 ± 13.8% of patients without new-onset CVD (p < 0.001). The mean new-onset CVD-free survival time in patients with > 30% and < 30% stenoses were 52.5 [95% confidence intervals (CIs) 50.0–54.9] and 66.5 (95% CIs 66.2–66.8) months, respectively (p < 0.001). The area under the receiver operating characteristic curve of the maximal arterial stenosis for new-onset CVD was 0.911. These results suggest that CRC patients are at risk for developing new-onset CVD, which is associated with reduced survival. Atherosclerotic burden in the aorta or both iliac arteries may help predict future CVD events.

A Retrospective Clinical Study on Cardiovascular Complications from Colorectal Cancer

“…The findings of this research are consistent with the existing literature on cardiovascular complications in CRC patients [2,48,49]. Moreover, we have furthered the understanding of oxidative stress and cardiovascular complications in patients with CRC, thus providing new clues for prevention and treatment.…”

“…Recent epidemiological data shows that CRC has become a significant burden in terms of incidence and mortality rates [1][2][3][4]. Despite advances in diagnostic and treatment approaches, the overall survival rate of CRC patients remains relatively low, indicating the need for further improvement in management strategies.…”

Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer

“…The 10-year cumulative incidence of new-onset cardiovascular disease and CHF was 57.4 and 54.5% for patients with stage I–III CRC compared with 22 and 18% for the matched cohort without cancer, respectively ( p < 0.001) ( 7 ). Correspondingly, a Korean cohort study reported 141 (4.9%) patients who developed new-onset CVD among postoperative CRC patients ( 8 ). These studies raised the increasing concern of CV-related adverse events among CRC survivors.…”

“…Postoperative chemotherapy is associated with an increased risk of CVD ( 7 , 8 ). Fluoropyrimidine is the backbone of chemotherapy in the adjuvant setting in patients with CRC.…”